绝经期激素治疗用于慢性疾病一级预防
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
| Population | Postmenopausal women | Postmenopausal women who have had a hysterectomy |
|---|---|---|
| Recommendation | Do not prescribe combined estrogen and progestin for the prevention of chronic conditions. Grade: D |
Do not prescribe estrogen for the prevention of chronic conditions. Grade: D |
| Risk Assessment | This recommendation applies to the average-risk population. Risk factors for a specific chronic disease or individual characteristics that affect the likelihood of a specific therapy-associated adverse event may cause a woman's net balance of benefits and harms to differ from that of the average population. | |
| Preventive Medications |
Although combined estrogen and progestin therapy (specifically, oral conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d) decreases the risk for fractures in postmenopausal women, there is an accompanying increased risk for serious adverse events, such as stroke, invasive breast cancer, dementia, gallbladder disease, deep venous thrombosis, and pulmonary embolism.
Estrogen therapy (specifically, oral conjugated equine estrogen, 0.625 mg/d) decreases the risk for fractures and has a small effect on the risk for invasive breast cancer, but it is also associated with important harms, such as an increased likelihood of stroke, deep venous thrombosis, and gallbladder disease. Neither combined estrogen and progestin therapy nor estrogen alone reduces the risk for coronary heart disease in postmenopausal women. |
|
| Balance of Harms and Benefits | The chronic disease prevention benefits of combined estrogen and progestin do not outweigh the harms in most postmenopausal women. | The chronic disease prevention benefits of estrogen are unlikely to outweigh the harms in most postmenopausal women who have had a hysterectomy. |
| Relevant USPSTF Recommendations | The USPSTF has made recommendations on screening for osteoporosis and the use of preventive medications for breast cancer, as well as other relevant interventions for the primary or secondary prevention of chronic diseases in women, such as medications for cardiovascular disease and screening for coronary heart disease, high blood pressure, lipid disorders, colorectal cancer, breast cancer, and dementia. These recommendations are available at http://www.uspreventiveservicestaskforce.org/. | |
全文地址：
上一篇： NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines)® Breast Cancer
下一篇： 钙与维生素D的膳食参考摄入量
学科代码：内科学 内分泌学与糖尿病 妇产科学 关键词：绝经期激素治疗 慢性疾病一级预防
文章来源：MDC
文章来源：MDC
MDC介绍： MD Consult 是爱思唯尔公司于1997年推出的新一代智慧型医学咨询平台，包含50多部著名医学参考书，88种全文医学期刊和北美临床系列杂志，10000篇患者手册，1000份诊疗指南，以及持续更新的药品信息，医学新闻，并支持PDA功能，为医生解答医学及科研问题，让医生紧贴第一手医学发展信息，并迅速以其优质的内容和方便时效的服务赢得了很高的声誉。 请点击申请试用并填写联系信息，我们将每月为前100位申请者发送带有用户名、密码及网页链接的电子邮件，请您注意查收！感谢您的参与及使用！请点击此处登录MD Consult。。马上访问MDC网站：http://www.mdconsult.com/
顶一下（0）
- 您可能感兴趣的指南
-
